Aspirin cost-effective for VTE prophylaxis after hip replacement
Daily aspirin ups bleeding risk
HealthDay News -- Aspirin is a cost-effective choice for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty, but the choice of aspirin versus low-molecular-weight heparin for patients younger than 80 years undergoing total knee arthroplasty is unclear, study findings indicate.
"For patients with no history of VTE, aspirin is a cost-effective choice for VTE prophylaxis following total hip arthroplasty, but the preferred choice following total knee arthroplasty depends on age and is uncertain for those younger than eighty years old," John T. Schousboe, MD, PhD, and Gregory A. Brown, MD, PhD, of the Park Nicollet Institute for Research & Education in Minneapolis reported in the Journal of Bone & Joint Surgery.
They conducted a modeling study to assess the cost-effectiveness of low-molecular-weight heparin compared with low-dose aspirin as VTE prophylaxis for two weeks following total joint (hip or knee) arthroplasty in patients with no history of VTE.
The threshold for cost-effectiveness was set at $100,000 (2010 U.S. dollars) per quality-adjusted life-year (QALY) gained.
The researchers found that, for total hip arthroplasty in patients at ages 55 and 70 years, costs per QALY gained for low-molecular-weight heparin compared with aspirin were $315,000 and $1.4 million, respectively. For patients aged 80 or 85 years, aspirin cost less and saved more QALYs than low-molecular-weight heparin.
For total knee arthroplasty in patients at ages 55, 70 and 85 years, costs per QALY gained for low-molecular-weight heparin compared with aspirin were $36,000, $112,000 and $448,000, respectively.
For patients undergoing total hip arthroplasty, and for patients 80 years or older undergoing total knee arthroplasty, probabilistic sensitivity analyses confirmed a low probability of cost-effectiveness for low-molecular-weight heparin. For patients younger than 80 years undergoing total knee arthroplasty, the most cost-effective choice for VTE prophylaxis is uncertain.